We protect your health through science

Investigation

Antibiotic Resistance

Research Lines

Content with Investigacion Neumococos .

Neumococos

Vigilancia epidemiológica de los serotipos y genotipos que causan enfermedad neumocócica invasiva (ENI) en España. Caracterización molecular de factores de virulencia de neumococo. Identificación y caracterización de proteínas de neumococo candidatas a vacuna. Evaluación de mecanismos de evasión de la respuesta inmune en Streptococcus pneumoniae. Impacto de los biofilms bacterianos en la persistencia del tracto respiratorio. Mecanismos de cronicidad de aislados clínicos de neumococo en pacientes con enfermedad pulmonar obstructiva crónica.

Research projects

Content with Investigacion Neumococos .

1: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones en pacientes con fibrosis quística provocadas por los patógenos Pseudomonas aeruginosa y Staphylococcus aureus: CF-TREAT

Referencia: CPP2022-009574 / MPY 375/23

Agencia Financiadora: Agencia Estatal de Investigación. MICINN.

Fecha Inicio:    01/12/2023
Fecha Fin:    30/11/2026
Financiación: 238.938 Euros
Investigadores principales: Roberto Díez Martínez, José E. Yuste Lobo y Pilar García Suárez

 

2: Título del proyecto: Desarrollo de enzibióticos para combatir infecciones humanas producidas por Enterococcus faecium resistente a vancomicina (ANTI‐VRE).
Proyecto CPP2021-009054 financiado por MICIU/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR

Investigadores principales: Roberto Díez Martínez, Jose Yuste Lobo y Mirian Domenech

Periodo: 18/11/2022 - 17/11/2025

Cuantía total: 231.455 €

3: Título del proyecto: Mecanismos de virulencia en patógenos respiratorios.
Entidad financiadora: Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (Convocatoria «Proyectos I+D+I» 2020 - Modalidades «Retos Investigación» y «Generación de Conocimiento»). Referencia: PID2020-119298RB-I00

Investigador principal: Jose Yuste Lobo

Periodo: 01/09/2021 - 30/08/2024

Cuantía total: 121.000 €

4: Título del proyecto: Efectividad de la vacuna antineumocócica conjugada 13-valente frente a la hospitalización por neumonía adquirida en la comunidad en adultos de 60 años o mayores, mediante un estudio de casos y controles modificado. Estudio CIBELES.

Investigadores principales: Jose Yuste Lobo y Ángel Gil de Miguel
Entidad financiadora: PFIZER. Referencia: MVP 249/20
Periodo: 23/02/2021 - 22/02/2025
Cuantía total: 168.000 €

5: Título del proyecto: Evolution of Invasive Pneumococcal Disease in Spain with special focus on the pathogenesis of serotypes 3, 8, 11A, 19A, 22F and 33F. Investigadores principales: Jose Yuste Lobo y Mirian Domenech.
Entidad financiadora: Merck Sharp & Dohme USA. Referencia: MVP 132/21
Período: 16/06/2021 - 15/12/2023
Cuantía total: 157.448€

6: Título del proyecto: Mecanismos de patogenicidad y protección en bacterias Gram-positivas causantes de enfermedad respiratoria y bacteriemia
Investigador principal: Jose Yuste Lobo
Entidad financiadora: MINECO. Referencia: SAF2017-83388-R
Periodo: 31/12/2017 - 30/06/2021
Cuantía total: 145.200 €

7: Título del proyecto: Characterization of susceptibility to cefditoren investigating penicillin resistant clinical isolates of Streptococcus pneumoniae.
Investigadores: Jose Yuste Lobo y Mirian Domenech Lucas
Entidad financiadora: Tedec Meiji Farma, S.A. Referencia: MVP 119/20
Periodo: 11/07/2020 – 10-07-2022
Cuantía total: 76.517 €

8: Título del proyecto: Impact of clinical isolates of serotypes 22F and 33F in the epidemiology and pathogenesis of Streptococcus pneumoniae.
Investigador principal: Jose Yuste Lobo
Entidad financiadora: Merck Sharp & Dohme España, S.A. Referencia: MVE 213/18
Periodo: 10/05/2018 - 30/05/2021
Cuantía total: 157.604 €

Publications

Sort
Category

Chikungunya virus infections among travellers returning to Spain, 2008 to 2014.

5. M.D. Fernandez-Garcia, M. Bangert, F. de Ory, A. Potente, L. Hernández, F. Lasala, L. Herrero, F. Molero, A. Negredo, A. Vázquez, T. Minguito, P. Balfagón, J. de la Fuente, S. Puente, E. Ramírez de Arellano, M. Lago, M.J. Martinez, J. Gascón, F. Norman, R. Lopez-Velez, E. Sulleiro, D. Pou, N. Serre, R. Fernández-Roblas, A. Tenorio, L. Franco, M.P. Sánchez-Seco (2016). Chikungunya virus infections among travelers returning to Spain, 2008-2014. EUROSURVEILLANCE 2016; 21(36):pii=30336.

PUBMED DOI

Genetic Characterization of Rubella Virus Strains Detected in Spain, 1998-2014.

6. A.O. Martínez-Torres, M.M. Mosquera, F. de Ory, A. González-Praetorius, J.E. Echevarría (2016). Genetic Characterization of Rubella Virus Strains Detected in Spain, 1998-2014. PLoS One. 11(9):e0162403

PUBMED DOI

Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG.

7. F. de Ory, M.E. Guisasola, P. Balfagón, J.C. Sanz. 2018. Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG. JOURNAL OF CLINICAL LABORATORY ANALYSIS; 32:e22203.

PUBMED DOI

Genomic non-coding regions reveal hidden patterns of mumps virus circulation in Spain, 2005 to 2015.

8. A.M. Gavilán, A. Fernández-García, A. Rueda, A. Castellanos, J. Masa-Calles, N. López-Perea, M.V. Torres de Mier, F. de Ory, J.E. Echevarría. 2018. Genomic non-coding regions reveal hidden patterns of mumps virus circulation in Spain, 2005 to 2015. EUROSURVEILLANCE, 2018;23(15):pii=17-00349.

PUBMED DOI

Comparative evaluation of indirect immunofluoresecence and NS-1 based ELISA for the determination of Zika virus specific IgM.

9. F. de Ory, M.P. Sánchez-Seco, A. Vázquez, M.D. Montero, E. Sulleiro, M.J. Martinez, L. Matas, F.J. Merino, and Working Group for the Study of Zika Virus Infections (WGSZVI). 2018. Comparative evaluation of indirect immunofluoresecence and NS-1 based ELISA for the determination of Zika virus specific IgM. VIRUSES 10, 379

PUBMED DOI

Measles virus genotype D4 strains with non-standard genome lengths circulated during the large outbreaks in Spain in 2011-2012

10. H. Gil, A. Fernández-García, M.M. Mosquera, J.M. Hübschen, A. Castellanos, F. de Ory, J. Masa, J.E. Echevarria. 2018. Measles virus genotype D4 strains with non-standard length M-F non-coding region circulated during the major outbreaks of 2011-2012 in Spain. PLOS ONE July 16, 2018.

PUBMED DOI

Hepatitis E genotype 3 genome: A comprehensive analysis of entropy, motif conservation, relevant mutations, and clade-associated polymorphisms

• Muñoz-Chimeno M, Rodríguez-Paredes V, García-Lugo MA, Avellón A. Hepatitis E genotype 3 genome: A comprehensive analysis of entropy, motif conservation, relevant mutations, and clade-associated polymorphisms. Front Microbiol. 2022 Oct 6;13:1011662.

PUBMED DOI

Frecuencia de sustituciones relevantes asociadas a resistencia en la región NS5A a elbasvir en el virus de la hepatitis C en pacientes con genotipo 1a en España

Palladino C, Esteban-Cartelle B, Mate-Cano I, Sánchez-Carrillo M, Resino S, Briz V. Frecuencia de sustituciones relevantes asociadas a resistencia en la región NS5A a elbasvir en el virus de la hepatitis C en pacientes con genotipo 1a en España Enferm Infecc Microbiol Clin. 2018; 36 (5): 262-267

PUBMED DOI

Content with Investigacion Neumococos .

List of staff

Additional Information

Our general objective is to provide early knowledge about any emerging antibiotic resistance mechanism in our country. This contribution of knowledge is based on transversal objectives that we consider key, such as 1) the ability to adapt research to emerging resistance problems, 2) the promotion of cooperative and multidisciplinary research studies working in networks with different Spanish and foreign centers, 3) the transfer of research results in an agile way to the clinical practice of the national health system, and 4) the promotion of the interrelation of research with reference, advice, training and dissemination seeking the empowerment of all. 

More specifically, our main scientific objectives are the characterization of the molecular bases of antibiotic resistance in pathogenic bacteria, the study of the molecular epidemiology and population structure of resistant bacteria, the characterization of the mobile genetic elements that carry resistance genes, and the development of diagnostic techniques and therapeutic alternatives against bacteria with extensive resistance to antibiotics. In this sense, research into the dissemination pathways of Enterobacteriaceae, Acinetobacter baumannii and carbapenemase-producing Pseudomonas aeruginosa (as a paradigm of extensive resistance and pan-resistance) is one of our current priority objectives.

Our general objective is to provide early knowledge about any emerging antibiotic resistance mechanism in our country. This contribution of knowledge is based on transversal objectives that we consider key, such as 1) the ability to adapt research to emerging resistance problems, 2) the promotion of cooperative and multidisciplinary research studies working in networks with different Spanish and foreign centers, 3) the transfer of research results in an agile way to the clinical practice of the national health system, and 4) the promotion of the interrelation of research with reference, advice, training and dissemination seeking the empowerment of all. 

More specifically, our main scientific objectives are the characterization of the molecular bases of antibiotic resistance in pathogenic bacteria, the study of the molecular epidemiology and population structure of resistant bacteria, the characterization of the mobile genetic elements that carry resistance genes, and the development of diagnostic techniques and therapeutic alternatives against bacteria with extensive resistance to antibiotics. In this sense, research into the dissemination pathways of Enterobacteriaceae, Acinetobacter baumannii and carbapenemase-producing Pseudomonas aeruginosa (as a paradigm of extensive resistance and pan-resistance) is one of our current priority objectives.

Content with Investigacion Neumococos .